US Stock MarketDetailed Quotes
KZIA Kazia Therapeutics
- 5.520
- +0.120+2.22%
Close Nov 1 16:00 ET
- 5.550
- +0.030+0.54%
Post 20:01 ET
18.37MMarket Cap-1502P/E (TTM)
5.760High5.400Low36.90KVolume5.400Open5.400Pre Close204.17KTurnover1.16%Turnover RatioLossP/E (Static)3.33MShares15.80052wk High5.30P/B17.50MFloat Cap1.86652wk Low--Dividend TTM3.17MShs Float158.500Historical High--Div YieldTTM6.67%Amplitude1.860Historical Low5.533Avg Price1Lot Size
About Kazia Therapeutics Company
Kazia Therapeutics Ltd. is a clinical stage oncology company, which engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Company Profile
SymbolKZIA
Company NameKazia Therapeutics
Listing DateJan 7, 1999
Founded1994
CEODr. John E. Friend, II,M.D.
MarketNASDAQ
Employees16
Securities TypeDR
ADS Ratio1.0 : 100.0
Fiscal Year Ends06-30
AddressThree International Towers,300 Barangaroo Avenue,Level 24
CitySydney
ProvinceNew South Wales (NSW)
CountryAustralia
Zip Code2000
Phone61-2-9472-4101
Company Executives
- Name
- Position
- Salary
- Dr. John E. Friend, II,M.D.
- Managing Director, Chief Executive Officer and Interim Chairman of the Board
- 1.58M
- Karen Krumeich
- Chief Financial Officer
- 1.05M
- Steven Coffey
- Independent Director
- 94.00K
- Ebru Davidson
- Independent Director
- 7.12K
- Bryce D. Carmine
- Independent Director
- 94.00K
- Anna Sandham
- Company Secretary
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data